Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Regina M. Carney is active.

Publication


Featured researches published by Regina M. Carney.


Pediatric Neurology | 2003

Identification of MeCP2 mutations in a series of females with autistic disorder.

Regina M. Carney; Chantelle M. Wolpert; Sarah A. Ravan; Mona D. Shahbazian; Allison E. Ashley-Koch; Michael L. Cuccaro; Jeffery M. Vance; Margaret A. Pericak-Vance

Rett disorder and autistic disorder are both pervasive developmental disorders. Recent studies indicate that at least 80% of Rett Disorder cases are caused by mutations in the methyl-CpG-binding protein 2 (MeCP2) gene. Since there is some phenotypic overlap between autistic disorder and Rett disorder, we analyzed 69 females clinically diagnosed with autistic disorder for the presence of mutations in the MeCP2 gene. Two autistic disorder females were found to have de novo mutations in the MeCP2 gene. These data provide additional evidence of variable expression in the Rett disorder phenotype and suggest MeCP2 testing may be warranted for females presenting with autistic disorder.


Neurobiology of Aging | 2013

Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians

Martin A. Kohli; Krista John-Williams; Ruchita Rajbhandary; Adam C. Naj; Kara Hamilton; Regina M. Carney; Clinton B. Wright; Elizabeth Crocco; Harry Gwirtzman; Rosalyn Lang; Gary W. Beecham; Eden R. Martin; John R. Gilbert; Michael Benatar; Gary W. Small; Deborah C. Mash; Goldie S. Byrd; Jonathan L. Haines; Margaret A. Pericak-Vance; Stephan Züchner

Recently, a hexanucleotide repeat expansion in the C9ORF72 gene has been identified to account for a significant portion of Caucasian families affected by frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Given the clinical overlap of FTD with Alzheimers disease (AD), we hypothesized that C9ORF72 expansions might contribute to AD. In Caucasians, we found C9ORF72 expansions in the pathogenic range of FTD/ALS (>30 repeats) at a proportion of 0.76% in AD cases versus 0 in control subjects (p = 3.3E-03; 1182 cases, 1039 controls). In contrast, no large expansions were detected in individuals of African American ethnicity (291 cases, 620 controls). However, in the range of normal variation of C9ORF72 expansions (0-23 repeat copies), we detected significant differences in distribution and mean repeat counts between Caucasians and African Americans. Clinical and pathological re-evaluation of identified C9ORF72 expansion carriers revealed 9 clinical and/or autopsy confirmed AD and 2 FTD final diagnoses. Thus, our results support the notion that large C9ORF72 expansions lead to a phenotypic spectrum of neurodegenerative disease including AD.


Neurology Genetics | 2016

ABCA7 frameshift deletion associated with Alzheimer disease in African Americans

Holly N. Cukier; Brian W. Kunkle; Badri N. Vardarajan; Sophie Rolati; Kara L. Hamilton-Nelson; Martin A. Kohli; Beth A. Dombroski; Derek Van Booven; Rosalyn Lang; Derek M. Dykxhoorn; Lindsay A. Farrer; Michael L. Cuccaro; Jeffery M. Vance; John R. Gilbert; Gary W. Beecham; Eden R. Martin; Regina M. Carney; Richard Mayeux; Gerard D. Schellenberg; Goldie S. Byrd; Jonathan L. Haines; Margaret A. Pericak-Vance

Objective: To identify a causative variant(s) that may contribute to Alzheimer disease (AD) in African Americans (AA) in the ATP-binding cassette, subfamily A (ABC1), member 7 (ABCA7) gene, a known risk factor for late-onset AD. Methods: Custom capture sequencing was performed on ∼150 kb encompassing ABCA7 in 40 AA cases and 37 AA controls carrying the AA risk allele (rs115550680). Association testing was performed for an ABCA7 deletion identified in large AA data sets (discovery n = 1,068; replication n = 1,749) and whole exome sequencing of Caribbean Hispanic (CH) AD families. Results: A 44-base pair deletion (rs142076058) was identified in all 77 risk genotype carriers, which shows that the deletion is in high linkage disequilibrium with the risk allele. The deletion was assessed in a large data set (531 cases and 527 controls) and, after adjustments for age, sex, and APOE status, was significantly associated with disease (p = 0.0002, odds ratio [OR] = 2.13 [95% confidence interval (CI): 1.42–3.20]). An independent data set replicated the association (447 cases and 880 controls, p = 0.0117, OR = 1.65 [95% CI: 1.12–2.44]), and joint analysis increased the significance (p = 1.414 × 10−5, OR = 1.81 [95% CI: 1.38–2.37]). The deletion is common in AA cases (15.2%) and AA controls (9.74%), but in only 0.12% of our non-Hispanic white cohort. Whole exome sequencing of multiplex, CH families identified the deletion cosegregating with disease in a large sibship. The deleted allele produces a stable, detectable RNA strand and is predicted to result in a frameshift mutation (p.Arg578Alafs) that could interfere with protein function. Conclusions: This common ABCA7 deletion could represent an ethnic-specific pathogenic alteration in AD.


Alzheimers & Dementia | 2014

Parkinsonism and distinct dementia patterns in a family with the MAPT R406W mutation

Regina M. Carney; Martin A. Kohli; Brian W. Kunkle; Adam C. Naj; John R. Gilbert; Stephan Züchner; Margaret A. Pericak-Vance

The Arg406Trp (R406W) missense mutation in the microtubule‐associated protein‐tau gene (MAPT) is a known cause of early‐onset dementia. Various dementia phenotypes have been described, including frontotemporal dementia (FTD), FTD with parkinsonism, and early‐onset Alzheimer disease (EOAD)‐like presentations.


Neurology Genetics | 2016

SORL1 mutations in early- and late-onset Alzheimer disease.

Michael L. Cuccaro; Regina M. Carney; Yalun Zhang; Christopher Bohm; Brian W. Kunkle; Badri N. Vardarajan; Holly N. Cukier; Richard Mayeux; Peter St George-Hyslop; Margaret A. Pericak-Vance

Objective: To characterize the clinical and molecular effect of mutations in the sortilin-related receptor (SORL1) gene. Methods: We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants. The phenotypic consequences associated with SORL1 mutations were characterized based on clinical reviews of medical records. Functional studies were completed to evaluate β-amyloid (Aβ) production and amyloid precursor protein (APP) trafficking associated with SORL1 mutations. Results: SORL1 alterations were present in 2 EOAD families. In one, a SORL1 T588I change was identified in 4 individuals with AD, 2 of whom had parkinsonian features. In the second, an SORL1 T2134 alteration was found in 3 of 4 AD cases, one of whom had postmortem Lewy bodies. Among LOAD cases, 4 individuals with either SORL1 A528T or T947M alterations had parkinsonian features. Functionally, the variants weaken the interaction of the SORL1 protein with full-length APP, altering levels of Aβ and interfering with APP trafficking. Conclusions: The findings from this study support an important role for SORL1 mutations in AD pathogenesis by way of altering Aβ levels and interfering with APP trafficking. In addition, the presence of parkinsonian features among select individuals with AD and SORL1 mutations merits further investigation.


Neurology Genetics | 2016

Segregation of a rare TTC3 variant in an extended family with late-onset Alzheimer disease

Martin A. Kohli; Holly N. Cukier; Kara L. Hamilton-Nelson; Sophie Rolati; Brian W. Kunkle; Stephan Züchner; Lindsay A. Farrer; Eden R. Martin; Gary W. Beecham; Jonathan L. Haines; Jeffery M. Vance; Michael L. Cuccaro; John R. Gilbert; Gerard D. Schellenberg; Regina M. Carney; Margaret A. Pericak-Vance

Objective: The genetic risk architecture of Alzheimer disease (AD) is complex with single pathogenic mutations leading to early-onset AD, while both rare and common genetic susceptibility variants contribute to the more widespread late-onset AD (LOAD); we sought to discover novel genes contributing to LOAD risk. Methods: Whole-exome sequencing and genome-wide genotyping were performed on 11 affected individuals in an extended family with an apparent autosomal dominant pattern of LOAD. Variants of interest were then evaluated in a large cohort of LOAD cases and aged controls. Results: We detected a single rare, nonsynonymous variant shared in all 11 LOAD individuals, a missense change in the tetratricopeptide repeat domain 3 (TTC3) gene. The missense variant, rs377155188 (p.S1038C), is predicted to be damaging. Affecteds-only multipoint linkage analysis demonstrated that this region of TTC3 has a LOD score of 2.66 in this family. Conclusion: The TTC3 p.S1038C substitution may represent a segregating, rare LOAD risk variant. Previous studies have shown that TTC3 expression is consistently reduced in LOAD patients and negatively correlated with AD neuropathology and that TTC3 is a regulator of Akt signaling, a key pathway disrupted in LOAD. This study demonstrates how utilizing whole-exome sequencing in a large, multigenerational family with a high incidence of LOAD could reveal a novel candidate gene.


Alzheimers & Dementia | 2016

Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk.

Timothy J. Hohman; Jessica N. Cooke-Bailey; Christiane Reitz; Gyungah Jun; Adam C. Naj; Gary W. Beecham; Zhi Liu; Regina M. Carney; J. M. Vance; Michael L. Cuccaro; Ruchita Rajbhandary; Badri N. Vardarajan; Li-San Wang; Otto Valladares; Chiao-Feng Lin; Eric B. Larson; Neill R. Graff-Radford; Denis A. Evans; Philip L. De Jager; Paul K. Crane; Joseph D. Buxbaum; Jill R. Murrell; Towfique Raj; Nilufer Ertekin-Taner; Mark W. Logue; Clinton T. Baldwin; Robert C. Green; Lisa L. Barnes; Laura B. Cantwell; M. Daniele Fallin

African‐American (AA) individuals have a higher risk for late‐onset Alzheimers disease (LOAD) than Americans of primarily European ancestry (EA). Recently, the largest genome‐wide association study in AAs to date confirmed that six of the Alzheimers disease (AD)‐related genetic variants originally discovered in EA cohorts are also risk variants in AA; however, the risk attributable to many of the loci (e.g., APOE, ABCA7) differed substantially from previous studies in EA. There likely are risk variants of higher frequency in AAs that have not been discovered.


Annals of Human Genetics | 2007

No Association between SNP rs498055 on Chromosome 10 and Late‐Onset Alzheimer Disease in Multiple Datasets

Xueying Liang; Nathalie Schnetz-Boutaud; Jackie Bartlett; Melissa Allen; Harry E. Gwirtsman; Don Schmechel; Regina M. Carney; John R. Gilbert; Margaret A. Pericak-Vance; Jonathan L. Haines

SNP rs498055 in the predicted gene LOC439999 on chromosome 10 was recently identified as being strongly associated with late‐onset Alzheimer disease (LOAD). This SNP falls within a chromosomal region that has engendered continued interest generated from both preliminary genetic linkage and candidate gene studies. To independently evaluate this interesting candidate SNP we examined four independent datasets, three family‐based and one case‐control. All the cases were late‐onset AD Caucasian patients with minimum age at onset ≥ 60 years. None of the three family samples or the combined family‐based dataset showed association in either allelic or genotypic family‐based association tests at p < 0.05. Both original and OSA two‐point LOD scores were calculated. However, there was no evidence indicating linkage no matter what covariates were applied (the highest LOD score was 0.82). The case‐control dataset did not demonstrate any association between this SNP and AD (all p‐values > 0.52). Our results do not confirm the previous association, but are consistent with a more recent negative association result that used family‐based association tests to examine the effect of this SNP in two family datasets. Thus we conclude that rs498055 is not associated with an increased risk of LOAD.


American Journal of Medical Genetics | 2008

Longitudinal Follow-Up of Late-Onset Alzheimer Disease Families

Regina M. Carney; Michael A. Slifer; Ping I. Lin; P. C. Gaskell; William K. Scott; C.F. Potocky; Christine M. Hulette; Kathleen A. Welsh-Bohmer; Donald E. Schmechel; J. M. Vance; Margaret A. Pericak-Vance

Historically, data for genetic studies are collected at one time point. However, for diseases with late onset or with complex phenotypes, such as Alzheimer disease (AD), restricting diagnosis to a single ascertainment contact may not be sufficient. Affection status may change over time and some initial diagnoses may be inconclusive. Follow‐up provides the opportunity to resolve these complications. However, to date, previous studies have not formally demonstrated that longitudinally re‐contacting families is practical or productive. To update data initially collected for linkage analysis of late‐onset Alzheimer disease (LOAD), we successfully re‐contacted 63 of 81 (78%) multiplex families (two to 17 years after ascertainment). Clinical status changed for 73 of the 230 (32%) non‐affected participants. Additionally, expanded family history identified 20 additional affected individuals to supplement the data set. Furthermore, fostering ongoing relationships with participating families helped recruit 101 affected participants into an autopsy and tissue donation program. Despite similar presentations, discordance between clinical diagnosis and neuropathologic diagnosis was observed in 28% of those with tissue diagnoses. Most of the families were successfully re‐contacted, and significant refinement and supplementation of the data was achieved. We concluded that serial contact with longitudinal evaluation of families has significant implications for genetic analyses.


Dementia and Geriatric Cognitive Disorders | 2007

Association Analysis of Genetic Polymorphisms in the CDC2 Gene with Late-Onset Alzheimer Disease

Xueying Liang; Nathalie Schnetz-Boutaud; Jackie Bartlett; Brent Anderson; Harry E. Gwirtsman; Don Schmechel; Regina M. Carney; John R. Gilbert; Margaret A. Pericak-Vance; Jonathan L. Haines

Background: Alzheimer disease (AD) is a complex neurodegenerative disorder resulting from multiple genetic and non-genetic factors. Linkage studies indicated that chromosome 10 has at least one locus for this disease. The cell division cycle 2 (CDC2) gene, which is close to one of the linkage regions, has previously been associated with the risk of AD with an odds ratio of 1.78. Biologically, CDC2, which is involved in paired helical filament-tau formation, is thought as a candidate gene in AD. Methods: In this study, six single nucleotide polymorphisms spanning the entire gene were selected and examined for association for late-onset AD (LOAD) in two large independent datasets. A family-based dataset including 1,337 Caucasian discordant sib pairs and an independent dataset of 745 Caucasian cases and 998 controls for LOAD were used. Family-based association tests and logistic regression conditional on the apolipoprotein E genotype and sex were applied to association study in family-based and case-control datasets, respectively. Results: Neither dataset demonstrated any association with LOAD in our samples with all p values >0.16. Conclusion: Our results suggest that if any contribution of common genetic variants in CDC2 to the risk of developing AD exists, it is likely to be very small.

Collaboration


Dive into the Regina M. Carney's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jonathan L. Haines

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adam C. Naj

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge